DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for B-cell neoplasm — screening already-approved drugs against its 16-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleB-cell neoplasm maps to a 16-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for b-cell neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tubulin alpha 1b (TUBA1B) — TUBA1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gtpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6S8L · 1.801 Å · ligand GUANOSINE-5'-TRIPHOSPHATE (GTP). Experimental structure, not a prediction.
What the evidence adds up to
Rituximab is established in non-transplant therapy for B-cell malignancies, and a review of 92 clinical trials (16 reviewed in detail) examined its emerging roles in haematopoietic cell transplantation. These include in vivo graft purging, maintenance after autologous transplantation, conditioning for allogeneic transplant, and treatment or prevention of chronic graft-versus-host disease and post-transplant lymphoproliferative disorder. The challenge identified in 2010 is how to incorporate rituximab for optimum efficacy in patients who come to transplant after relapse on rituximab-containing therapy.
Unconjugated antibodies represent an alternative approach for non-Hodgkin's lymphoma and chronic lymphocytic leukaemia, driven by frequent relapse and development of refractory disease. A 2002 review discussed pharmacology, dosage, administration guidelines, and side-effect management for this drug class, but provided no response rates or survival data from controlled trials.
By 2014, novel immunotherapies under investigation for B-cell lymphomas and leukaemias included new disease targets, novel delivery strategies, and immune-modifying agents. The review noted that these therapies may show early potential but also acknowledged unique toxicities and limitations such as difficulties in administration. No concrete response rates, survival figures, or sample sizes from these investigational agents were reported in the abstracts.
What remains missing across these reviews are prospective randomised trials that directly compare rituximab-containing transplant strategies against alternatives in patients who have already failed rituximab, as well as adequately powered studies of newer immunotherapies that report objective response rates and long-term survival. Patient stratification by prior treatment history and disease subtype is not addressed in the available summaries.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Expert Opinion on Biological Therapy · 2010 · 6 citations
Rituximab in hematopoietic cell transplantation
AbstractIMPORTANCE OF THE FIELD: The success of rituximab therapy in managing B cell malignancies supports its widespread application in both autologous and allogeneic hematopoietic cell transplantation. AREAS COVERED IN THIS REVIEW: We searched the PubMed database using the terms rituximab, stem cell transplant, autologous, or allogeneic and limited the search to clinical trials in English. In total, 92 trials were identified and 16 were reviewed in detail for significance of rituximab intervention. In this review, we will examine rituximab's emerging roles in: i) in vivo graft purging; ii) maintenance following autologous transplantation; iii) allogeneic transplant conditioning; and iv) the rationale for its use in the treatment/prevention of chronic graft-versus-host disease and post-transplant lymphoproliferative disorder. WHAT THE READER WILL GAIN: The reader will gain an understanding of the use of rituximab not only in transplants for B cell malignancies, but also its extension to other diseases where we are learning that B cells are involved in the pathogenesis. TAKE HOME MESSAGE: With rituximab firmly established in the non-transplant therapy of B cell malignancies, the new challenge in transplantation is how to incorporate the drug for optimum efficacy in those patients coming to transplant with relapse after rituximab-containing therapy.
Using Unconjugated Antibodies as an Immunotherapeutic Approach to Treatment of B-cell Neoplasms
AbstractB-cell neoplasms have the sixth highest mortality incidence and one of the largest rates of increase of all malignancies. Frequent relapse and the development of refractory disease in this patient group have stimulated research to find alternative treatments. The use of unconjugated antibodies offers a new approach to the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. This article will explore the pharmacology, dosage, and administration guidelines as well as side effect management of the available drugs in this classification. Expectations for future approaches to the treatment of B-cell neoplasms will be discussed.
American Journal of Therapeutics · 2014 · 2 citations
Novel Immunotherapies for B-Cell Lymphomas and Leukemias
AbstractCurrent immunotherapeutic agents under investigation have the potential to significantly expand our ability to effectively treat B-cell malignancies. New disease targets, novel strategies to deliver therapy, and advanced agents that work to manipulate the immune system are a few of the ways immunotherapy has quickly evolved. Novel targeted and immune-modifying therapies may demonstrate early potential but unique toxicities and other limitations, such as difficulties in administration, must also be acknowledged. This review provides a comprehensive assessment of the current immunotherapies under investigation against B-cell malignancies.
[Paclitaxel combined with platinum-based chemotherapy as second-line treatment in patients with advanced non-small cell lung cancer: A forty case-report].
AbstractBACKGROUND: To evaluate the activity and toxicity of paclitaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC). METHODS: Forty patients with recurrent advanced NSCLC were enrolled. Thirty-six patients were managed with regular regimen. Paclitaxel 135 mg/m², 3 h, on day 1; DDP 75 mg/m² or carboplatin 300-350 mg/m² on day 2. Four patients were managed with weekly regimen. Paclitaxel 60 mg/m²,3 h, on days 1,8,15; DDP 75 mg/m² on day 2. It was repeated every three or four weeks, up to two to four cycles. RESULTS: Thirty-six cases were evaluated for response and 27 for survival. The objective response rate was 13.9% (5/36). At least one tumor-related symptom relief was observed in 21 patients (58.3%). The median survival duration was 26.4 weeks and 1-year survival rate was 8% (4/36). The main toxicities included myelosuppression, fatigue and myalgia-arthralgia neuropathy. CONCLUSIONS: Paclitaxel has advantage to be well-tolerated and improve tumor-related symptom. Further studies with standardization of dose and regimen will be needed to clarify its role in the second-line treatment.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
